Table 2. Association between different polymorphisms and recurrence-free survival of patients.

	Epirubicin					MMC
	Recurrence	All patients	MST *	Log-rank P	Adjusted HR (95% CI)	Recurrence	All patients	MST *	Log-rank P	Adjusted HR (95% CI)
GSTP1 rs1695
AA	22	78	76.7	0.002	1.00 (reference)	16	61	64.4	0.408	1.00 (reference)
AG	26	46	40.4		3.29 (1.63–6.63)	23	51	52.6		0.63 (0.05–7.46)
GG	2	6	23.3		5.18 (1.05–25.62)	1	2	62.5		1.56 (0.80–3.07)
AA	22	78	76.7	0.001	1.00 (reference)	16	61	64.4	0.218	1.00 (reference)
AG+GG	28	52	40.7		3.47 (1.75–6.89)	24	53	53.9		1.54 (0.79–3.01)
GSTO1 rs4925
CC	29	82	67.4	0.019	1.00 (reference)	26	68	55.1	0.231	1.00 (reference)
AC	15	40	49.0		1.89 (0.94–3.83)	6	30	74.5		0.34 (0.11–1.09)
AA	6	8	28.2		3.23 (1.16-8.94)	8	16	45.3		1.12 (0.38–3.33)
CC	29	82	67.4	0.042	1.00 (reference)	26	68	55.1	0.404	1.00 (reference)
AC+AA	21	48	43.8		1.96 (1.05–3.70)	14	46	62.8		1.20 (0.60–2.44)
GSTO2 rs156697
CC	8	15	35.4	0.170	1.00 (reference)	9	21	51.9	0.550	1.00 (reference)
CT	16	50	51.4		0.88 (0.31–2.51)	9	38	63.2		0.75 (0.22–2.62)
TT	26	65	67.7		0.51 (0.22–1.22)	22	55	55.3		1.12 (0.48–2.63)
CC	8	15	35.4	0.071	1.00 (reference)	9	21	51.9	0.778	1.00 (reference)
CT+TT	42	115	64.3		0.56 (0.25–1.26)	31	93	59.9		0.94 (0.42–2.14)
ABCB1 rs3747802
TT	48	126	28.1	0.580	1.00 (reference)	38	111	28.0	0.105	1.00 (reference)
TC	2	3	71.3		0.33 (0.05–1.99)	2	2	22.0		4.81 (0.99–23.50)
CC	0	1	21.0		0.00	0	1	8.0		0.00
ABCB1 rs3213619
TT	47	114	29.1	0.335	1.00 (reference)	36	103	25.8	0.323	1.00 (reference)
TC	3	9	32.7		0.91 (0.27–3.09)	3	6	31.2		0.46 (0.06–3.75)
CC	0	7	23.7		0.00	1	5	64.0		1.17 (0.33–4.17)

^*Mean survival time was defined as the mean time before recurrence.